



THERAPEUTICS

August 2, 2016

## Tobira Therapeutics to Present at the 36th Annual Canaccord Genuity Growth Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the Canaccord Genuity Growth Conference.

- | Location: Boston
- | Presentation date: Wednesday, August 10, 2016
- | Presentation time: 5:00 p.m. ET

A live webcast and 30-day archive of this presentation will be available at <http://ir.tobiratx.com>.

### About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at [www.tobiratx.com](http://www.tobiratx.com).

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160802005454/en/>

### Tobira Investor & Media Contact:

Ian Clements, Ph.D., +1 650-351-5013

[ir@tobiratherapeutics.com](mailto:ir@tobiratherapeutics.com)

or

### BrewLife Media Contact:

Kelly Boothe, Ph.D., +1 425-946-1076

[kboothe@brewlife.com](mailto:kboothe@brewlife.com)

Source: Tobira Therapeutics, Inc.

News Provided by Acquire Media